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Background: Medication adherence is important in managing COPD. This study analyzed real-
world use of inhaled medications for COPD to characterize relationships between daily dosing
frequency, adherence, healthcare resource utilization, and cost.
Methods: This retrospective study used a large administrative claims database covering 8 million
insured lives in theUS from1999 to 2006. Patientswere stratified based on the recommendeddaily
dosing frequencyof their first COPDdrug claim followingCOPDdiagnosis. Adherencewasmeasured
using proportion of days covered (PDC) over 12 months following treatment initiation. Healthcare
resource use included inpatient, outpatient, and emergency room visits. Amultivariate regression
model assessed the relationship between adherence and one-year healthcare resource use,
controlling for demographics, comorbidities, and baseline resource use. Unit healthcare costs
were obtained from the 2005 Medical Expenditure Panel Survey, adjusted to 2008 dollars.
Results: Based on a sample of 55,076 COPD patients, adherence was strongly correlated with
dosing frequency. PDCwas43.3%,37.0%, 30.2%and23.0% forQD, BID,TID, andQIDpatient cohorts,
respectively. Regression analysis showed that one-year adherencewas correlatedwith healthcare
resourceutilization.For1000COPDpatients, a5%point increase inPDC reducedtheannualnumber
of inpatient visits (2.5%) and emergency room visits (1.8%) and slightly increased outpatient
visits (þ.2%); the net reduction in annual cost was approximately $300,000.425 8131; fax: þ1 617 425 8001.
up.com (M.S. Duh).
0 Elsevier Ltd. All rights reserved.
436 E.L. Toy et al.Conclusion: COPDpatientswho initiated treatmentwith once-daily dosing had significantly higher
adherence than other daily dosing frequencies. Better treatment adherence was found to yield
reductions in healthcare resource utilization and cost.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized as a chronic airflow limitation that is not fully
reversible. The airflow limitation is usually progressive and
is associated with an abnormal inflammatory response of
the lungs to gaseous or particulate irritants.1 Although
COPD is under-diagnosed in the US, the prevalence of the
disease in the US has been estimated at 23.6 million adults
(about 13.9% of the adult population), and within the next
decade COPD is expected to become the third leading cause
of death.2 The economic burden of COPD is also substantial.
In 2007, the total cost of COPD in the United States was
approximately $42.6 billion, including $26.7 billion incurred
in direct healthcare expenditures, $8 billion in indirect
morbidity costs, and $7.9 billion in indirect mortality
costs.3
Although pharmacotherapies have not been shown to
modify the long-term decline of lung function in COPD
patients, a variety of effective medications are available to
prevent and control symptoms, improve health status, and
reduce the occurrence of COPD exacerbations.1 A central
part of COPD management is the use of bronchodilators,
which includes beta-agonists, anti-cholinergics, and meth-
ylxanthines. Regular use of long-acting beta-agonists
(LABAs), short-acting anti-cholinergics (SAACs), and long-
acting anti-cholinergics (LAACs) has been shown to improve
health status. Orally administered methylxanthines are
another type of bronchodilator, but current guidelines note
a preference for inhaled bronchodilators (e.g., beta-
agonists and anti-cholinergics), which have less potential
for toxicity.1 Glucocorticosteroids are anti-inflammatory
agents that are also used to manage COPD. These drugs are
often used to treat exacerbations of COPD, as their use in
the management of stable COPD is limited to specific
indications.1 More recently, therapies that combine
multiple bronchodilators or that combine a bronchodilator
and glucocorticosteroid together in a single inhaler have
been developed. For example, a combination of a LABA and
inhaled glucocorticosteroid has been shown to be more
effective than each individual drug.1
COPD is a chronic disease in which effective manage-
ment requires long-term adherence to pharmacotherapies.
Although researchers have used a variety of different
definitions, patient adherence to treatment generally
relates to the extent to which a patient obtains and
consumes his or her medication as prescribed. Non-adher-
ence is a significant risk factor for mortality, morbidity,
hospitalizations, and reduced quality of life.4,5 Adherence
levels observed in clinical trials may be around 70e90%, but
in real-life clinical practice, observed levels of adherence
are typically far lower (e.g., 10e40%).6 Research suggests
that many factors influence adherence to therapy. Thesefactors are patient’s age, co-payment, type of prescriber,
comorbidities, concomitant medications, knowledge about
and faith in the treatment, and complexity of the treat-
ment regimen.7e10 Research also suggests that the
lengthier and more complicated the treatment regimen,
the greater the likelihood of non-adherence, and that
patients prefer once-daily COPD therapy over therapies
that require multiple dosings per day.11,12
This study examines adherence levels among patients
prescribed inhaled COPD medications. Using data from real-
world clinical practice, the study investigates the rela-
tionship between adherence and daily dosing frequency, as
well as the healthcare resource utilization and cost impli-
cations of higher adherence.
Methods
Data sources
This study used an administrative claims database consisting
of de-identified, Health Insurance Portability and Account-
ability Act (HIPAA)-compliant medical and prescription drug
dispensing claims from employees and retirees (including
their spouses and dependants) of 40 self-insured Fortune 500
companies located throughout the United States, between
1999 and 2006. Together these companies cover a broad
array of industries and job classifications (e.g., financial
services, manufacturing, telecommunications, energy, util-
ities, airline, railroad, entertainment, pharmaceutical, and
food and beverage). It contains enrollment records and
complete medical and pharmacy claims for approximately
8.4 million beneficiaries: about 7.6 million beneficiaries less
than 65 years of age (non-Medicare) and approximately
800,000 beneficiaries over the age of 65.
Because of possible Medicare dual coverage for patients
above the age of 65, the administrative claims database
was not used as the source of cost data. To estimate
healthcare costs experienced by these patients, unit costs
for inpatient and outpatient services were obtained from
the 2005 survey of the Medical Expenditure Panel Survey
(MEPS). MEPS is a nationally representative large-scale
survey of families and individuals (non-institutionalized),
their medical providers, and employers across the United
States that has been ongoing since 1996. It provides cost
information at the patient level compiled from both patient
payments for services and insurance payments. The data
available from MEPS are considered to be the one of the
most complete sources of national data on the cost and use
of healthcare and health insurance coverage.13 In order to
have a more accurate cost estimate on the national level,
patient data were weighted to compensate for over-
sampling of certain populations and non-response to the
survey.13 All costs from the 2005 survey were adjusted to
Dosing frequency, adherence, and cost of COPD treatment 4372008 dollars using the Medical Care Consumer Price Index
(Medical CPI).14
Study population
The study focused on patients who were naı¨ve users of
commonly used, inhaled COPD medications. The COPD
drugs of interest included LABAs and LAACs. Although SAACs
can be used on an as-needed basis, these drugs are also
used as regular, maintenance therapy and thus were also
included. Patients taking combinations of these afore-
mentioned drugs were also eligible.
Patients were included in the study if they satisfied the
following inclusion criteria. First, patients had to have been
diagnosed with COPD, based on the presence of at least one
claim with a diagnosis code for COPD (International Clas-
sification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes for chronic bronchitis, emphysema,
chronic obstructive asthma, and chronic airway obstruction
not elsewhere classified: 491, 492, 493.2, and 496). Second,
patients were required to have at least two pharmacy
claims for a COPD drug of interest following a diagnosis of
COPD. The index date was defined as the date of a patient’s
first prescription claim for a COPD drug of interest. Third,
patients needed to have continuous eligibility for 6 months
prior to (i.e., baseline period) and 1 year after the index
date. Fourth, patients who received one of the COPD drugs
of interest in a non-pharmacy setting (i.e., in a physician’s
office or hospital setting) were excluded as it was not
possible to determine the specific drug information about
the dose and days supply of drug provided to the patient.
All medical, prescription medication, and eligibility
recordswere extracted for the baseline period (i.e. 6months
preceding the index date) and the one-year study period
(i.e., 12 months following the index date) for each patient.
Patientswere categorized into separate cohorts basedon the
daily dosing frequency of the COPD drug prescription that
was filled on the index date. Drugs were classified as once-
daily (QD), twice-daily (BID), three times daily (TID), or four
times daily (QID) primarily using the dosing frequencyTable 1 Drugs included in each daily dosing frequency.
Daily Dosing
Frequencya,b
Active Ingredient
QD tiotropium
BID salmeterol þ fluticasone combination
formoterol þ budesonide combination
formoterol
salmeterol
TID ipratropium bromide (nasal spray form)c
QID ipratropium bromide (nasal spray form)c
ipratropium bromide (nebulizer form)
albuterol þ ipratropium combination
a Based on FDA-approved prescribing information.
b QD Z Once-Daily, BID Z Twice-Daily, TID Z Three Times
Daily, and QID Z Four Times Daily.
c Atrovent HFA, an ipratropium bromide inhalation aerosol,
was classified QID. All other ipratropium bromide nasal sprays
were classified TID.recommended in FDA-approved prescribing information
labels (See Table 1).15
Study outcomes
Patient adherence was measured using the proportion of
days covered (PDC), defined as the proportion of days in
a given time interval that a patient had a drug available.6,16
This study considered PDC measured over a one-year
interval: the sum of all the days supply for all prescriptions
with the daily dosing frequency of the initial drug was
divided by 365 days. As a sensitivity analysis, PDC was also
calculated for shorter intervals (9, 6, and 3 months).
Healthcare resource utilization outcomes included the
number of inpatient visits, the number of inpatient days,
and the number of outpatient visits and emergency room
(ER) visits over 365 days of observation following the index
date. Utilization of healthcare resources was based on
medical claim type and place of service. Utilization was not
restricted to that associated with COPD diagnoses; all-
cause utilization was measured in this study to capture
complications associated with COPD that may not have
been explicitly billed under COPD. The cost associated with
each healthcare utilization visit (inpatient, outpatient, and
ER visits) was taken from estimates produced by the Agency
for Healthcare Research and Quality using cost adjusted
MEPS data.
Statistical analyses
Comparisons of demographic baseline variables and PDC
between COPD patients in each daily dosing frequency
group were performed using Wilcoxon tests for continuous
outcomes and Chi-square tests for categorical outcomes.
Resource utilization was analyzed using negative bino-
mial regression to control confounding factors. Covariates
in the model included age, gender, PDC (over 12 months),
and baseline resource utilization (inpatient, outpatient and
ER visits). The model also adjusted for the presence of
comorbidities during the 6 months pre-index period,
including Charlson comorbidity index (CCI), depression/
anxiety, diabetes, coronary artery disease, renal failure,
liver failure, hypertension, asthma, pneumonia, influenza,
and emphysema. The Charlson comorbidity index is a score
of 17 comorbid diseases that are weighted for disease
severity.17 In addition, variables related to the baseline
severity of COPD were included (claims for oxygen therapy,
spirometry tests, pulmonologist visits, and glucocorticos-
teroid use).18 These surrogates for COPD severity were used
because direct measures of COPD severity (i.e., forced
expiratory volume in 1 s, FEV1) were not available in the
claims data. To analyze the relationship between adher-
ence level and healthcare resource use and cost, the esti-
mated regression model was used to predict the effect of
improving adherence. Holding all other patient character-
istics constant, the measured PDC value for each patient
was increased by five percentage points to calculate the
predicted utilization and costs associated with this hypo-
thetical improvement in adherence. The difference
between the predicted and actual observed utilization is
interpreted as the incremental effect of a five percentage
438 E.L. Toy et al.point increase in adherence. The outcomes were expressed
as annual resource use and costs for a hypothetical cohort
of 1000 patients with COPD. The cost impacts associated
with the predicted changes in utilization were calculated
by applying unit cost estimates from MEPS. All statistical
analyses were carried out using SAS v9.2 software (SAS
Institute, Cary, NC).
Results
Baseline patient characteristics
A total of 55,076 patients met the criteria for inclusion in
the study. The most frequent daily dosing frequency class
of the initial drug taken as of the index date was BID, which
accounted for 45.4% of the population, followed by QID
(39.7%), TID (8.3%), and QD (6.7%). As shown in Table 2,
patients in the QD class were more often male (p < .0001).
The average age of patients was approximately 69 years,
with the exception that patients in the BID cohort were
younger (p < .0001). In general, QD and QID patients ten-
ded to have non-respiratory comorbidities more often.
However, there was no clear relationship between daily
dosing frequency class and respiratory comorbidities.
Patients in the QD class had more severe COPD, asTable 2 Baseline characteristics of COPD patients stratified by
QD (N Z 3678) BID (N Z 25,011)
Age, years (Mean, SD) 69.0 11.01 64.0 14.21
Seniors, age 65 (n,%) 2407 65.4% 12,762 51.0%
Male (n, %) 1960 53.3% 10,742 43.0%
Region (n, %)
Northeast 984 26.8% 6175 24.7%
Midwest 1006 27.4% 6890 27.6%
South 1445 39.3% 9521 38.1%
West 243 6.6% 2425 9.7%
Charlson Comorbidity
Index - CCI (Mean,SD)8
1.83 (1.65) 1.50 (1.50)
Comorbid Conditions (n,%)b
Depression/Anxiety 122 3.3% 1011 4.0%
Diabetes Mellitus 629 17.1% 3392 13.6%
Coronary Artery/Heart Disease 915 24.9% 4331 17.3%
Renal Failure 156 4.2% 681 2.7%
Liver Failure 73 2.0% 365 1.5%
Hypertension 882 24.0% 4877 19.5%
Respiratory Comorbidities (n, %)b
Asthma 497 13.5% 7626 30.5%
Pneumonia and Influenza 496 13.5% 2703 10.8%
Emphysema 436 11.9% 1532 6.1%
Oxygen Therapy (n, %)b 400 10.9% 1209 4.8%
Spirometry Test (n, %)b 1399 38.0% 7290 29.2%
Pulmonologist Visit (n, %)b 1211 32.9% 5151 20.6%
Glucocorticoid Use (n, %)b
Inhaled Glucocorticoid 790 21.5% 21,548 86.2%
Systemic Glucocorticoid 690 18.8% 5805 23.2%
a P-values are for comparison of QD vs. BID, QD vs. TID, and QD vs. Q
test for categorical outcomes.
b The CCI, all comorbidities, oxygen therapy, spirometry tests, pulm
the 6 month period preceding the index date.evidenced by the higher fraction of patients in that class
who had claims for oxygen therapy, spirometry tests, and
pulmonologist visits; these differences compared to the
other daily dosing frequency classes were statistically
significant (p < .0001). Glucocorticosteroid use was highest
among patients in the BID class.
Adherence
During the 12 month study period, patients initiated on QD
treatment had an average PDC of 43.3% (Table 3). There
was a consistent trend of PDC declining as the frequency of
dosing increased: the PDC for BID, TID, and QID was 37.0%,
30.2%, and 23.0% (p < .0001), respectively. As a sensitivity
analysis, PDC was also calculated for intervals of 9, 6, and 3
months post index date. Adherence levels were consis-
tently higher for QD.
Utilization and cost
The multivariate regression model found that higher
adherence was correlated with reduced urgent care usage
(i.e., the annual number of inpatient days, inpatient visits,
and ER visits). As expected, patients who were adherent to
their COPD therapy had a tendency to utilize more routinedosing class of first COPD treatment.
p-valuea TID (N Z 4544) p-valuea QID (N Z 21,843) p-valuea
<.0001 69.0 11.58 (.53) 68.9 12.38 .66
<.0001 3018 66.4% .35 14,084 64.5% .26
<.0001 2172 47.8% <.0001 10,557 48.3% <.0001
.01 1065 23.4% .001 4708 21.6% <.0001
.80 1406 30.9% <.0001 7190 32.9% <.0001
.16 1600 35.2% <.0001 8486 38.9% .61
<.0001 473 10.4% <.0001 1459 6.7% .87
<.0001 1.72 (1.64) <.0001 1.85 (1.82) (.05)
.04 187 4.1% .06 1105 5.1% <.0001
<.0001 654 14.4% .001 3635 16.6% .49
<.0001 968 21.3% <.0001 5191 23.8% .14
<.0001 163 3.6% .13 1144 5.2% .01
.02 69 1.5% .11 440 2.0% .91
<.0001 961 21.2% .002 5143 23.6% .57
<.0001 693 15.3% .03 3013 13.8% .65
<.0001 538 11.8% .03 4068 18.6% <.0001
<.0001 413 9.1% <.0001 1750 8.0% <.0001
<.0001 308 6.8% <.0001 1544 7.1% <.0001
<.0001 878 19.3% <.0001 4288 19.6% <.0001
<.0001 730 16.1% <.0001 4421 20.2% <.0001
<.0001 1290 28.4% <.0001 4434 20.3% .10
<.0001 957 21.1% .01 5435 24.9% <.0001
ID. Wilcoxon test is used for continuous outcomes and Chi-square
onologist visits, and glucocorticosteroid use are measured during
Table 3 Proportion of days covereda (PDC) for COPD
patients at twelve, nine, six, and three month intervals
stratified by dosing class of first COPD treatment.
QD BID TID QID
After Twelve Months
N 3678 25,011 4544 21,843
Mean PDC 43.3% 37.0% 30.2% 23.0%
St. Dev. .32 .29 .28 .24
p-valueb N/A <.0001 <.0001 <.0001
After Nine Months
N 4418 26,757 4700 23,613
Mean PDC 46.7% 40.1% 33.4% 25.4%
St. Dev. .32 .29 .28 .24
p-valueb N/A <.0001 <.0001 <.0001
After Six Months
N 5195 28,575 4900 25,615
Mean PDC 52.8% 45.6% 38.4% 30.1%
St. Dev. .31 .29 .29 .25
p-valueb N/A <.0001 <.0001 <.0001
After Three Months
N 6056 30,814 5097 28,159
Mean PDC 67.6% 60.9% 51.6% 42.6%
St. Dev. .29 .29 .31 .27
p-valueb N/A <.0001 <.0001 <.0001
a PDC is defined as the ratio of the days supply a given drug
during the observation period to the total number of days in the
observation period.
b P-values are for comparison of QD vs. BID, QD vs. TID, and
QD vs. QID. Wilcoxon test is used for continuous outcomes and
Chi-square test for categorical outcomes.
Dosing frequency, adherence, and cost of COPD treatment 439care services (i.e., outpatient visits). Table 4 shows that for
a cohort of 1000 patients with COPD, a five percentage
point increase in adherence level would lead to a 2.5%
reduction in inpatient visits on average. On a percentage
basis, a smaller reduction for emergency room visits and
a slight increase in outpatient visits was predicted.
These predicted changes in healthcare utilization were
analyzed with respect to cost. Based on MEPS data, average
unit healthcare costs were assumed to be $9124 for
a hospital visit, $110 for an outpatient visit, and $505 for an
ER visit; the average cost per inpatient day was unavailable
in MEPS. On an aggregate basis for 1000 COPD patients, the
predicted change in healthcare utilization would result inTable 4 The effect of increasing PDC on predicted 12 month m
patients.
Resource Use
Utilization Baseline
PDC
Baseline
PDC þ 5 Percentage
Points
Differenc
(%)
Hospital Visits 1275 1243 33 (2
Inpatient Daysb 5906 5720 186 (3
Outpatient Visits 16,981 17,010 29 (.
ER Visits 817 802 15 (1
a The average costs using MEPS data were $9124 for a hospital visit
b Average cost per inpatient day was unavailable from MEPS.an estimated cost decrease of $296,598 for inpatient visits
and $7410 for ER visits, with a slight cost increase of $3219
for outpatient visits; the net effect would amount to
a reduction in total annual medical costs of $300,789, or
about a 2.2% reduction.Discussion
COPD is a chronic disease that, for most patients, typically
necessitates the regular use of pharmacotherapies to
control symptoms and improve quality of life. Accordingly,
COPD treatment regimens that increase the likelihood of
higher medication adherence levels would be expected to
contribute to improved disease management. This study
used a large, retrospective administrative claims database
to measure the relationships between the daily dosing
frequency of commonly used COPD medications, adher-
ence, healthcare resource use, and costs.
In a sample of 55,076 patients initiating drug treatment
for COPD, we found that adherence level was strongly
associated with daily dosing frequency. COPD drugs with QD
dosing had the highest adherence level, and adherence
declined consistently with BID, TID, and QID dosings.
This finding is consistent with the literature. Iskedjian
et al. conducted a meta-analysis of adherence to a variety
of hypertension drugs and found that QD regimens had
higher adherence levels than regimens with more frequent
daily dosings.19 Claxton et al. reviewed studies across
a variety of therapeutic areas that measured adherence
using electronic monitoring techniques and likewise found
that adherence declined with medications that required
more frequent dosing.20 Several studies have also examined
adherence in the context of COPD treatment. Bender et al.
measured adherence to a combination fluticasone-salme-
terol drug and found one-year PDC levels at approximately
22%; they noted that this adherence was substantially lower
than that estimated from clinical trials and markedly
discrepant with practice guidelines.21 Cramer 7 and
Breekveldt-Postma et al.6 reported that adherence to tio-
tropium (QD dosing) was higher than for ipratropium (QID)
and for drugs that were dosed as two or more times daily
(i.e., LABA, LABA þ inhaled glucocorticosteroids).
However, these COPD-related studies did not focus specif-
ically on the relationship between adherence and dosing
frequency.ean healthcare resource use and cost based on 1000 COPD
Costa
e Baseline
PDC
Baseline PDC
þ 5 Percentage
Points
Difference (%)
.6%) $11,635,099 $11,338,501 -$296,598 (2.6%)
.1%) e e e
2%) $1,867,863 $1,871,082 $3219 (.2%)
.8%) $412,658 $405,248 -$7410 (1.8%)
, $110 for an outpatient visit, and $505 for an ER visit.
440 E.L. Toy et al.A second finding of this study was that higher adherence
levels were associated with lower healthcare resource
utilization and cost in the year after initiating treatment for
COPD. The study population was modeled using a multivar-
iate regression model that controlled for various factors
that may influence adherence, such as age, gender, respi-
ratory and non-respiratory comorbidities, and surrogates
for COPD severity.10,18 The regression model was then used
to predict the effect of a five percentage point increase in
PDC, holding all other factors constant. In a hypothetical
population of 1000 COPD patients, this improvement in
adherence was predicted to reduce the annual number of
hospitalizations by approximately 2.5%. There were minor
predicted changes to the number of outpatient visits (slight
increase) and emergency room visits (slight decrease), but
as the cost of COPD care is driven by hospitalizations,3 the
predicted change in net costs was about 2.2%.
The relationship between adherence and healthcare
resource utilization and cost has been analyzed elsewhere. A
review by Muszbek et al. reported that in 23 studies covering
treatment of diabetes, hypertension, heart disease/failure,
and dyslipidemia, higher adherence was generally found to
be associated with lower overall healthcare cost.22 The
present study extends this literature to show that the inverse
relationship between adherence and utilization and cost is
observed in the context of COPD treatments.
This study suggests that the effective management of
COPD can be aided by consideration of the dosing
frequency of drug treatments prescribed to patients. Drugs
with fewer daily dosings are associated with improved
adherence, which in turn are associated with lower
healthcare resource use and cost. This is consistent with
the general findings of studies in other therapeutic areas.
Much of this literature examined oral medications,22 and
this study confirms that there are similar patterns in the
context of inhaled medications.
Several limitations exist in this study. First, adherence to
COPD treatments was measured using administrative claims
data. A claim for a prescription refill does not necessarily
mean that a patient is taking the medication as prescribed,
as some patients may obtain refills before a prescription
runs out, or in the case of the medications examined in the
present study, patients may not be using inhalers correctly.
While techniques such as electronic monitoring may offer
a more accurate method of measuring adherence, these
data are not readily available and where data are available
sample sizes are small; using claims data provides a larger
study population. Although different approaches exist to
measure adherence, we are not aware of factors that would
differentially affect treatment patterns across daily dosing
frequency classes and therefore bias the comparisons of the
daily dosing frequency classes. Claims data also are subject
to coding errors or incomplete records. Second, COPD
severity could not be measured directly (i.e., based on
spirometry tests), as claims databases typically do not
contain such information. COPD severity is correlated with
resource utilization, adherence, and treatment choice, and
therefore can act as a confounding factor in the analysis.
However, the regression analysis of resource utilization
included a variety of covariates that are indirect measures
for COPD severity. This statistical approach reduces the
potential for bias. Our understanding of this topic would beenhanced by future research utilizing more detailed clinical
and spirometric data. Third, our analysis is limited to
patients that are initiating treatment of COPD and there-
fore is unlikely to include patients with severe COPD. These
results may not be generalized to other settings or patient
groups. As patients gain more experience with inhaled
medications or as the frequency and severity of symptoms
change over time, the relationships between daily dosing
frequency, adherence, resource use, and cost may differ
from that observed among treatment-naı¨ve patients.
Fourth, complete data on costs were not available in the
claims database. The cost analysis therefore relied on
a unit cost approach using data from the MEPS database,
which may not accurately reflect the actual costs experi-
enced by the patients in the sample.
Conclusions
This study found that adherence to the initial drug treat-
ment of COPD was associated with dosing frequency, with
QD dosing having the highest adherence levels relative to
BID, TID or QID. In addition, improved adherence was
associated with a reduction in healthcare resource utiliza-
tion and cost. A five percentage point increase in PDC was
estimated to reduce annual healthcare resource use and
costs by approximately 2.2%. This study suggests that
dosing frequency should be an important consideration in
developing effective strategies for managing COPD.
Acknowledgement
Funding for this research was provided by Novartis Phar-
maceuticals Corporation, East Hanover, NJ.Conflict of interest statement
Toy, Beaulieu, McHale, Welland, and Duh are employees of
Analysis Group, Inc., which received research funds from
Novartis. Plauschinat and Swensen are employees and
stockholders of Novartis, which develops products in the
area of COPD.
References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease. 2008 update. Avail-
able at, http://www.goldcopd.com [accessed 31.07.09.].
2. Mannino DM, Braman S. The epidemiology and economics of
chronic obstructive pulmonary disease. Proc Am Thorac Soc
2007;4:502e6.
3. U.S. Department of Health and Human Services. National
Institutes of Health. National Heart Lung and Blood Institute.
Morbidity and mortality: 2007 chart book on cardiovascular,
lung and blood diseases.
4. Ramsey SD. Suboptimal medical therapy in COPD: exploring the
causes and consequences. Chest 2000;117(Suppl. 2):33Se7S.
5. Rand CS. Patient adherence with COPD therapy. Eur Respir Rev
2005;14(96):97e101.
6. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JJ,
Herings RMC. Enhanced persistence with tiotropium compared
Dosing frequency, adherence, and cost of COPD treatment 441with other respiratory drugs in COPD. Respir Med 2007;101:
1398e405.
7. Cramer JA. Partial medication compliance: the enigma in poor
medical outcomes. Am J Manag Care 1995;1:45e52.
8. Cramer JA, Spilker B. Patient compliance in medical practice
and clinical trials. New York: Raven Press; 1991.
9. Cochrane GM, Horne R, Chanez P. Compliance in asthma.
Respir Med 1999;93(11):763e9.
10. George J, Kong DC, Thoman R, Stewart K. Factors associated
with medication nonadherence in patients with COPD. Chest
2005;128(5):3198e204.
11. Sackett DL, Haynes RB. Compliance with therapeutic regi-
mens. Baltimore: John Hopkins University Press; 1976.
12. Venebles TL, Addlestone MB, Smithers AJ. A comparison of the
efficacy and patient acceptability of once daily budesonide via
turbuhaler and twice daily fluticasone propionate via a disc-
inhaler at an equal dose of 400mcg in adult asthmatics. Br J
Clin Res 1996;7:15e32.
13. Stagnitti MN, Beauregard K, Solis A. Design, methods, and field
results of the Medical Expenditure Panel Survey Medical
Provider Component (MEPS MPC)d2006 calendar year data,
methodology report no. 23. Rockville, MD: Agency for
Healthcare Research and Quality. Available at, http://www.
meps.ahrq.gov/mepsweb/data_files/publications/mr23/
mr23.pdf; November 2008 [accessed 20.08.09.].
14. Bureau of Labor Statistics. Measuring Price change for medical
care in CPI. Accessed online at, http://www.bls.gov/cpi/
cpifact4.htm [accessed 12.6.09.].15. Prescribing Information Labels were obtained from the U.S.
Food and Drug Administration website. Available at, http://
www.accessdata.fda.gov/scripts/cder/ob/default.cfm
[accessed September 2008].
16. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC,
Avorn J. Long-term persistence in use of statin therapy in
elderly patients. JAMA 2002;288:455e61.
17. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity
index for use with ICD-9-CM administrative data: differing
perspectives. J Clin Epidemiol 1993;46:1075e109. discussion
1081e1090.
18. Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G.
Development of a COPD severity score. Curr Med Res Opin
2006;22(9):1679e87.
19. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A,
Mittman N, et al. Relationship between daily dose frequency
and adherence to antihypertensive pharmacotherapy:
evidence from a meta-analysis. Clin Ther 2002;24(2):302e16.
20. Claxton AJ, Cramer J, Pierce C. A systematic review of the
associations between dose regimens and medication compli-
ance. Clin Ther 2001;23(8):1296e310.
21. Bender BG, Pedan A, Varasteh LT. Adherence and persistence
with fluticasone propionate/salmeterol combination therapy.
J Allergy Clin Immunol 2006;118(4):899e904.
22. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The
economic consequences of noncompliance in cardiovascular
disease and related conditions: a literature review. Int J Clin
Pract 2008;62(2):338e51.
